NeoStem intends to sell its common stock through a public offering

Company will sell shares, warrants via joint bookrunners Lazard, JMP

By Devika Patel

Knoxville, Tenn., July 18 - NeoStem, Inc. plans a public offering of stock and warrants, according to a prospectus supplement filed Monday with the Securities and Exchange Commission.

Lazard Capital Markets, LLC and JMP Securities are the joint bookrunners; Morgan Joseph TriArtisan LLC, Maxim Group LLC and National Securities Corp. are the co-managers.

Proceeds will be used for working capital, including research and development of cell therapeutic product candidates, expansion of business units and other general corporate purposes.

The New York-based company collects, processes and stores adult stem cells for autologous use in the treatment of cardiac disease, autoimmune disorders and other conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.